During clinical trials, pharma's lack effective advance warning of upcoming trial events and resultant changes in trajectory - as such, they are forced to continue non-working trials, and not take proactive actions on trials that are working
AI enabled events prediction engine
Gen AI based trial events prediction engine for sponsor stakeholders (initial focus on AE’s, SAE’s, hospitalizations) that delivers real-time insights to enable in-trial adjustments and improved execution
Patient Stratification for Precision Medicine
Patient clustering during a study will help sponsors identify patient cohorts that show a high drug response with the least number of adverse events.
This precision medicine technique can be used to boost trial success rates and drug efficacy (similar to how a biomarker is used for drug prescription, e.g. Keytruda with PD-L1 biomarker) to reduce unwanted prescriptions and increase payer reimbursement; the marketing label will state who is eligible to take the drug
Chatbots for real-time trial insights
How can Gen AI insights improve your drug trials?
With real-time insights, make operational study updates or stop a non-working trial sooner.
Plan additional studies based on the trial insights, is a sub-group working better, are there biomarkers that can increase drug efficacy or should there be any changes made to the inclusion/exclusion criteria?
Understand the drug better compared to competitors. Are there aspects of the drug that can be improved including dose, time of administration, and method of administration?
Generate additional insights to support your drug submissions. Can you claim higher efficacy and lower side effects, parameters that would increase your reimbursement prospects?
Plan for future studies, or in the case of adaptive studies, get insights on what additional tweaks you can make in real-time to improve study outcomes.
Selected by ERA (top accelerator) for winter cohort Jan 24, one of just 16 out of a very large pool of applicants, provides funding and growth platform
The founders are Vinodh Balaraman and Sridhar Byrapppa, both tech-savvy repeat entrepreneurs. Between us, we have 40+ years of pharma industry experience and expertise in business growth and execution. We have experienced the problems with drug development firsthand.
Vinodh Balaraman, Co-Founder and CEO
Vinodh is a world-class healthcare exec with a proven track record of building tech-based businesses and is a repeat entrepreneur. He has worked on large life sciences consulting assignments and led multifold growth in many situations, including as a Senior Partner at ZS and SVP at Atos. He is an IIT Chennai graduate and has an MBA from Chicago Booth
Sridhar Byrappa, Co-Founder and CSO
Sridhar has operational experience at large pharma companies (Merck, Wyeth, Schering Plough, BMS and Stryker). He has a Ph.D. in Microbiology and has firsthand experience with the travails of drug development and executing large global clinical trials. It is our collective effort to bring cutting-edge technologies to drug development - speed up drug trials, reduce development failure rates, and get a greater number of drugs to the market.
Speed up your drug trials with real-time trial insights